Naijipu Abuduaini
State Key Laboratory Of Medical Genomics
Shanghai, 200020, China
Shanghai, 200020, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Discovery and Characterization of Benzamide Derivatives as Highly Potent SUCNR1 Antagonists for Cancer Immunotherapy.
Journal: Journal of medicinal chemistry
Published: May 08, 2026
DHODH is a synthetic lethal target in PIK3CA-mutant colorectal cancer.
Journal: Cell reports
Published: January 29, 2026
A multicohort, biomarker-driven phase 2 trial of personalized total neoadjuvant therapy with targeted agents for high-risk rectal cancer (The TRAINER study).
Journal: Signal transduction and targeted therapy
Published: November 12, 2025
Integrative analysis reveals the role of SUMOylation-related patterns in shaping the tumor microenvironment and predicting treatment sensitivity of colorectal cancer.
Journal: Translational cancer research
Published: October 08, 2025
Targeting EP2/EP4-driven expansion of suppressive VSIG4high macrophages overcomes immunotherapy resistance in colorectal cancer.
Journal: Cell reports
Published: September 13, 2025
Optimizing total neoadjuvant therapy in locally advanced rectal cancer: risk stratification should not be overlooked.
Journal: Future oncology (London, England)
Published: May 22, 2025
Short-term outcomes of transanal endoscopic intersphincteric resection for locally advanced rectal cancer after neoadjuvant chemoradiotherapy: A single-center retrospective cohort study.
Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
Published: November 08, 2024
Optimizing outcomes in anastomotic recurrence of rectal cancer: Efficacy of transanal total mesorectal excision.
Journal: Current problems in surgery
Published: July 04, 2024
Natural orifice specimen extraction surgery versus small-incision assisted laparoscopic radical right hemicolectomy.
Journal: Future oncology (London, England)
Published: December 18, 2023
Berberrubine is a novel and selective IMPDH2 inhibitor that impairs the growth of colorectal cancer.
Berberrubine is a novel and selective IMPDH2 inhibitor that impairs the growth of colorectal cancer.
Journal: Biochemical pharmacology
Published: August 14, 2023
Last Updated: 09/26/2026